CRISPR: Pursuit of profit poisons collaboration

The CRISPR–Cas9 patent battle demonstrates how overzealous efforts to commercialize technology can damage science, writes Jacob S. Sherkow.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature (London) 2016-04, Vol.532 (7598), p.172-173
1. Verfasser:	Sherkow, Jacob S.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208 706/689/280 Academies and Institutes - economics Academies and Institutes - legislation & jurisprudence comment Cooperative Behavior CRISPR-Cas Systems - genetics Humanities and Social Sciences Inventions - economics Inventions - legislation & jurisprudence Licensure - economics multidisciplinary Ownership - economics Patents as Topic - legislation & jurisprudence Prenatal Diagnosis - economics RNA, Small Interfering - economics RNA, Small Interfering - therapeutic use Science Science (multidisciplinary) Technology Transfer Time Factors Universities - economics Universities - legislation & jurisprudence
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The CRISPR–Cas9 patent battle demonstrates how overzealous efforts to commercialize technology can damage science, writes Jacob S. Sherkow.
ISSN:	0028-0836 1476-4687
DOI:	10.1038/532172a